GC Cell Corporation (KOSDAQ:144510)

Market Cap	302.80B
Revenue (ttm)	172.92B
Net Income (ttm)	-82.24B
Shares Out	15.03M
EPS (ttm)	-5,473.02
PE Ratio	n/a
Forward PE	n/a
Dividend	100.00 (0.49%)
Ex-Dividend Date	n/a

Volume	28,570
Average Volume	74,363
Open	21,050
Previous Close	21,000
Day's Range	20,400 - 21,050
52-Week Range	16,940 - 38,000
Beta	1.30
RSI	47.71
Earnings Date	Aug 14, 2025

About GC Cell

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 752
• Stock Exchange: KOSDAQ
• Ticker Symbol: 144510

Financial Performance

In 2024, GC Cell's revenue was 174.45 billion, a decrease of -6.98% compared to the previous year's 187.54 billion. Losses were -73.90 billion, 42368.9% more than in 2023.